Do You Need an ECG or Blood Tests Before ADHD Medication?

No, an ECG isn’t routinely required before starting ADHD medication in Australia. Your GP checks blood pressure, heart rate and weight instead, and only orders an ECG if you have specific cardiac risk factors. This guide covers exactly what’s checked, when, and how often, once you’re on medication.

Your ADHD medication monitoring schedule at a glance

Phase	How often	What’s checked
Before starting	Once, at your initial assessment	Diagnosis confirmation, education or employment circumstances, substance use and diversion risk, medical history, current medicines, height and weight, baseline heart rate and blood pressure
During dose titration	Reviewed regularly by your GP, with adverse effects checked at each dose change	Symptom response, side effects, dose adjustment
Heart rate and blood pressure specifically	Before and after each dose change, and at least every 6 months	Compared with the normal range for your age
Once stable	Individualised to your needs, condition and response, with a full annual review at minimum	Symptom control, side effects, weight if indicated, whether a period off medication is worth discussing

ABOUT MY SPECIALIST GP

Your GP can now assess ADHD. We made the getting-there part easier.

We explain how ADHD assessment works in Australia, and connect you with independent GPs who assess and treat it.

Find and book a GP. Browse independent GPs who assess ADHD, by state, and book on the GP’s own profile page.
Get the GP-Ready ADHD Dossier. Questionnaires, an observer report, your history and your documents, organised into one file for your GP.

TWO WAYS TO START

Start wherever you are.

Book with a listed GP, or prepare your file first and take it to any GP you choose.

Find and book a GP

Get the GP-Ready ADHD Dossier

My Specialist GP is an education and connection platform. We are not a clinic and we do not diagnose or prescribe; the independent GPs listed here do.

Baseline assessments before starting ADHD medication

Before prescribing any ADHD medication, stimulant or non-stimulant, your GP completes a comprehensive assessment. Recommendation 5.1.2 (CPP) of the Australian ADHD clinical practice guideline sets out what this should include:

Confirmation the diagnosis criteria are met: your GP checks the ADHD diagnosis itself before prescribing
Education or employment circumstances: how ADHD is affecting study or work
Substance use and diversion risk: a risk assessment for substance misuse and for the medication being diverted to someone else
Medical history: personal and family history, including any conditions that might rule out a specific medication
Current medication list: interactions with other drugs, particularly those affecting heart rhythm or blood pressure
Height and weight: measured and compared with the normal range for your age
A cardiovascular assessment: baseline heart rate and blood pressure, recorded with an appropriately sized cuff and compared with the normal range for your age. Stimulant medicines raise heart rate by an average of about 3 to 6 beats per minute, so knowing your baseline matters

This baseline assessment is part of your initial consultation, and it’s the same regardless of which stimulant your GP is considering. See our guide to how GPs choose between dexamphetamine, Vyvanse and Ritalin for how that separate decision is made.

Do you need an ECG before starting stimulants?

No, not routinely. Recommendation 5.1.2 (CPP) of the Australian ADHD clinical practice guideline is direct on this: an ECG is not needed before starting stimulants, atomoxetine or guanfacine, unless you have one of the features in recommendation 5.1.3 (below) or a co-occurring condition being treated with medicines that may raise cardiac risk. The UK NICE guideline takes the same approach. Routine ECG screening for every ADHD patient isn’t supported by the current evidence and rarely changes management.

Recommendation 5.1.3 (CCR) says you should be referred for a cardiology opinion before starting a stimulant if you have:

A history of congenital heart disease or previous cardiac surgery
A history of sudden death in a first-degree relative under 40, suggesting a cardiac cause
Shortness of breath on exertion, compared with your peers
Fainting on exertion
Palpitations that are rapid, regular, and start and stop suddenly
Chest pain suggesting a cardiac cause
A heart murmur (not counting innocent murmurs picked up in children)
Hypertension

If none of these apply to you, an ECG is unlikely to be part of your pre-medication workup. If your GP does order one, it doesn’t mean they’re worried. It means they’re being thorough based on something in your history.

This is one of the more reassuring parts of starting ADHD medication. The pre-medication workup for a physically healthy adult is closer to a routine check than a cardiac work-up: blood pressure, pulse, weight, and a conversation about your history. Most people are cleared to start at their first or second consultation.

What blood tests are (and are not) required

Your GP may request blood tests to check your general health, and to rule out medical problems that can mimic or contribute to ADHD symptoms, such as thyroid disorders, low iron or anaemia.

These are targeted investigations based on your clinical picture, not blanket screening. If your GP orders blood tests before starting ADHD medication, ask what they’re checking for. The answer should be specific to your situation.

Common reasons a GP orders blood tests before or during ADHD treatment include ruling out an underactive thyroid, which can mimic poor concentration and low energy, and checking iron levels, since low iron has been linked to attention and fatigue symptoms in some patients. Neither is specific to ADHD, and a normal result doesn’t rule ADHD in or out. It simply removes another explanation before your GP focuses on medication.

Ongoing monitoring schedule, in detail

The table above summarises the schedule. Here’s what each phase involves.

Titration phase (first 4 to 8 weeks)

During dose titration, recommendation 5.1.5 (CPP) says the treating clinician should review your progress regularly, with adverse effects checked at every dose change. The guideline doesn’t set a fixed interval; how often you’re seen depends on your GP’s judgement and how you’re responding. Each visit covers symptom response, side effects (appetite, sleep, mood, heart rate, anxiety), and dose adjustment. This frequent contact is normal and expected; it doesn’t mean something is wrong. See our guide to what to expect in the first three months for what this looks like week by week.

Stabilisation phase (months 2 to 6)

Once your dose is stable and side effects are manageable, recommendation 5.7.1 (CPP) says follow-up moves to an individualised schedule, based on a chronic disease management approach: how often you’re seen depends on things like your response, any co-occurring conditions and how you’re coping day to day, rather than a fixed monthly slot. Heart rate and blood pressure are checked at least every 6 months regardless (recommendation 5.7.7, CCR). This phase confirms the medication is working consistently and that early side effects, particularly appetite suppression, aren’t causing problems.

Maintenance phase (6 months onward)

After six months of stable treatment, your GP continues to see you at an individualised interval (recommendation 5.7.1, CPP). Heart rate and blood pressure are checked before and after every dose change, and at least every 6 months regardless (recommendation 5.7.7, CCR). A full annual review revisits the areas discussed when you started treatment. The Vyvanse and Concerta product information both require this annual review as a minimum, specifically to confirm treatment is still needed and to check blood pressure and cardiovascular status.

The guideline’s own planned-break recommendation (5.7.6, CCR) is specifically for children and adolescents whose height growth has slowed on medication, to allow “catch-up” growth over school holidays. It doesn’t recommend a routine adult medication break. What it does say for adults is to monitor weight if indicated, rather than as a fixed routine. Separately, your GP may still raise trialling a period off medication as part of good ongoing care. Methylphenidate’s own product information supports this kind of periodic re-evaluation in general terms, without specifying how often. If your dose needs adjusting rather than pausing, see our guide to how to tell if your ADHD medication dose needs adjusting.

What your GP checks at each review appointment

A good ADHD medication review covers more than blood pressure. At each review, your GP should assess:

Symptom control: how your core ADHD symptoms (inattention, impulsivity, restlessness) have been since the last visit. Standardised rating scales like the ASRS can track changes over time.
Side effects: appetite and weight changes, sleep quality, mood (including anxiety and irritability), dry mouth, headaches
Cardiovascular: blood pressure and resting heart rate, compared to your baseline
Weight: the guideline says weight should be monitored in adults if indicated, rather than as a routine at every visit; because appetite suppression is common, many GPs check in on it anyway. Significant unintentional weight loss warrants a dose review or dietary support.
Mental health: ADHD medications don’t treat comorbid anxiety or depression directly. Your GP should screen for worsening of these conditions, particularly during the first few months.
Functional improvement: whether the medication is helping in the areas that matter to you: work performance, relationships, daily task completion, emotional regulation.
Medication adherence: whether you’re taking it consistently, and if not, why not. Barriers to adherence (cost, side effects, forgetting) need to be addressed, not judged.

If your GP isn’t covering these areas, bring them up yourself. You’re entitled to a thorough review, and the details you bring directly shape how your GP adjusts your treatment plan.

When your GP refers to a specialist

Most ADHD medication management happens in general practice. Your GP refers to a specialist when the situation falls outside routine management:

Cardiology referral: if any of the features in recommendation 5.1.3 develop during treatment (see the ECG section above), or if your blood pressure is consistently above the normal range for your age (recommendation 5.1.4, CCR)
Psychiatry referral: if comorbid conditions (severe anxiety, bipolar disorder, substance use) complicate medication management, or you haven’t responded adequately to two or more medications
Dietitian referral: if stimulant-related appetite suppression is causing clinically significant weight loss or nutritional deficiency
Sleep specialist referral: if medication-related insomnia persists despite dose timing adjustments and sleep hygiene measures

Referral isn’t a failure of GP management. It’s your GP recognising when a specific area needs focused attention from someone with additional training in that domain.

This page is general information about ADHD medication in Australia, not advice about your individual treatment. Do not start, stop or change a dose without talking to the clinician who prescribed it. If you experience chest pain, fainting, or thoughts of self-harm, contact your prescriber or call emergency services on 000.

Frequently asked questions

Do I need a blood test before starting ADHD medication?

Not routinely. Your GP may order targeted blood tests if something in your history or examination suggests a reason to, such as checking for thyroid problems or anaemia. Blood tests aren’t a blanket requirement for everyone starting ADHD medication.

Is an ECG required before starting Vyvanse or dexamphetamine?

No, not routinely. Recommendation 5.1.2 of the Australian ADHD guideline says an ECG isn’t needed before starting stimulants, atomoxetine or guanfacine unless you have one of the cardiac features in recommendation 5.1.3, such as a history of heart disease, a family history of sudden cardiac death under 40, or symptoms like chest pain or fainting on exertion. Your GP will decide if you need one based on your history.

How often should I see my GP after starting ADHD medication?

During dose titration, the Australian ADHD guideline says your GP should review you regularly, without setting a fixed interval; it depends on how you’re responding. Once your dose is stable, follow-up becomes individualised to your needs. Heart rate and blood pressure are checked before and after every dose change, and at least every 6 months regardless.

How often should my heart rate be checked once I’m on ADHD medication?

The guideline says heart rate and blood pressure should be checked before and after every dose change, and at least every 6 months once you’re stable (recommendation 5.7.7). If your resting heart rate is unusually high or keeps climbing, your GP may check it more often or refer you for a cardiology opinion.

Which ADHD medication needs cardiac screening first?

None of them require routine cardiac screening before starting, including Vyvanse, dexamphetamine, Ritalin and Concerta. The decision to order an ECG depends on your personal and family cardiac history, not on which medication you’re prescribed.

What happens at an annual ADHD medication review?

An annual review reassesses your overall treatment plan. Your GP measures blood pressure, heart rate and weight, reviews symptom control and side effects, screens for comorbid conditions, assesses functional improvement in daily life, and discusses whether a medication break or dose adjustment is worth considering.

Where GPs can prescribe ADHD medication, state by state
Find a GP who assesses ADHD in your state

Sources

AADPA Australian Evidence-Based Clinical Practice Guideline for ADHD, First Edition, October 2022, Summary of Recommendations (adhdguideline.aadpa.com.au, recommendations 5.1.2, 5.1.3, 5.1.4, 5.1.5, 5.7.1, 5.7.6 and 5.7.7, read 4 September 2026)
UK NICE Guideline NG87, Attention deficit hyperactivity disorder: diagnosis and management (nice.org.uk/guidance/ng87)
TGA Product Information: Aspen Dexamfetamine, dexamfetamine sulfate (Aspen Pharmacare Australia), TGA eBS document CP-2023-PI-02524-1, read directly on TGA eBS 4 September 2026
TGA Product Information: Vyvanse, lisdexamfetamine dimesilate (Takeda Pharmaceuticals Australia), TGA eBS document CP-2013-PI-02051-1, PI V12.0 (CCDS V40), read directly on TGA eBS 4 September 2026
TGA Product Information: Ritalin and Ritalin LA, methylphenidate hydrochloride (Novartis Pharmaceuticals Australia), TGA eBS document CP-2010-PI-03175-3, read directly on TGA eBS 4 September 2026
TGA Product Information: Concerta, methylphenidate hydrochloride (Janssen-Cilag), TGA eBS document CP-2009-PI-00919-3, API v3.0, read directly on TGA eBS 4 September 2026

General health information

This article is general health information only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always speak with a qualified health professional before making any changes to your medication or treatment plan.

MySpecialistGP is a health information and GP directory service operated by Webbed Feet Pty Ltd. Read our Medical Disclaimer.